US Patent Issued to Takeda Pharmaceutical on July 29 for "Subcutaneous administration of anti-CD38 antibodies" (California Inventors)

ALEXANDRIA, Va., July 30 -- United States Patent no. 12,371,506, issued on July 29, was assigned to Takeda Pharmaceutical Co. Ltd. (Osaka, Japan).

"Subcutaneous administration of anti-CD38 antibodies" was invented by Martin Dahl (San Diego), Eric Fedyk (San Deigo, Calif.), Robert Evans (San Diego) and Lin Zhao (San Diego).

According to the abstract* released by the U.S. Patent & Trademark Office: "Methods of administering isolated anti-CD38 antibodies at low dosages subcutaneously are disclosed. The methods provide an effective treatment for autoimmune diseases and cancers, including hematologic diseases. Also disclosed are unit dosage forms for the anti-CD38 antibodies."

The patent was filed on Jan. 14, 2019, under Application No. 16/96...